Pylarify (piflufolastar F18) injection - radiopharmaceutical

Ended Awarded Last action

Contract number
36C25222F0142
Awardee
Awarding agency
Obligated
$402,547

Award facts

Contract value 100% obligated
$402,546.98 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price
Place of performance
North Billerica, Billerica, MA 01862, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00003 -$29,622
Supplemental Agreement for work within scope P00002 $115,948
Supplemental Agreement for work within scope P00001 $140,543
Original award $175,679

About this award

Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and subsidiary of Lantheus Holdings, Inc., has been awarded a $402,546.98 firm fixed price delivery order for PYLARIFY (PIFLUFOLASTAR F18) INJECTION - RADIOPHARMACEUTICAL against its Pharmaceuticals and Drugs Federal Supply Schedule contract by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12. The delivery order has a completion date of February 26, 2024 and was awarded on March 9, 2022. PYLARIFY is a radioactive diagnostic agent used in positron emission tomography scans to aid in the detection of prostate cancer, consistent with Progenics Pharmaceuticals' product offerings to federal agencies. No set-aside designation was applied to this award.

Quick answers

Who was awarded contract 36C25222F0142?

36C25222F0142 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 12 (Veterans Health Administration) on March 9, 2022.

How much is contract 36C25222F0142 worth?

The government has obligated $402,547 on 36C25222F0142.

Is contract 36C25222F0142 an order under another contract?

Yes. 36C25222F0142 is a delivery order under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).

Was contract 36C25222F0142 competed?

The extent of competition for 36C25222F0142 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award